Innovation

Our Q4 and full-year 2023 earnings report

February 1, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Merck’s (NYSE: MRK) Q4 and full-year 2023 results reflect sustained growth across oncology and vaccines. Our company announced Q4 worldwide sales of $14.6 billion, an increase of 6% from Q4 2022. Full-year 2023 worldwide sales were $60.1 billion, an increase of 1% from full-year 2022. ​

“2023 was another very strong year for Merck. I am extremely pleased by the progress we’ve made to develop and deliver transformative therapies and vaccines that will help save and improve lives around the world. We reached more than 500 million people with our medicines last year alone, over half of which were donations, including through our program to treat river blindness,” said Rob Davis, chairman and chief executive officer. “We also made investments of approximately $30 billion in research and development in our ongoing effort to discover, develop and collaborate to propel the next generation of impactful innovations. As we move forward, I’m confident that our strong momentum will continue, underpinned by the unwavering dedication of our talented global team.”​

Merck anticipates full-year 2024 worldwide sales to be between $62.7 billion and $64.2 billion.​

Take a look at the infographic below for more details on Q4 and full-year 2023 results.

Download infographic

primary article image